Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?

Key Points Novo Nordisk has lost its lead in the weight loss market. The company could face even more competition going forward. However, its deep pipeline should enable it to remain a leader in this market. 10 stocks we like better than Novo Nordisk › Several years ago, Novo Nordisk (NYSE: NVO) -- which is now branding itself as Novo -- was performing so well that it was improving the entire economy of its home country, Denmark. The company was riding the wave of soaring demand for its GLP-1 medicines, Wegovy and Ozempic. However, Novo Nordisk has lost significant market value due to stiff competition in its core market, primarily from a single company, Eli Lilly (NYSE: LLY) .